Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Neupogen (09853464), Neupogen (01968017). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Filgrastim
Form:
10 of 10 products shown
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Nivestym · DIN 02485575 · 300 mcg/0.5 mL · injection solution-0.5mL pre-filled syringe
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Nivestym · DIN 02485575
Manufacturer: Pfizer Canada Inc.; listing date 2020-07-31
Health Canada: Marketed since 2020-05-11 · brand NIVESTYM · ATC L03AA02 FILGRASTIM · form Solution · route Subcutaneous, Intravenous · ingredients FILGRASTIM 300 MCG/0.5ML · company Pfizer canada ulc · schedule Prescription, Schedule d
DIN 02485575: Nivestym
Raw flags: sec3=Y
Item: 201600056; group id 269; item number 0544; lccId None; manufacturer id PFI
Source form: Inj Sol-0.5mL Pref Syr; strength: 300mcg/0.5mL
Recorded listing: General benefit
Source prices (unrounded): $105.6798; ministry $105.6798
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485575
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97581
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485575
Shortage record checked October 6, 2026
Filra · DIN 02556537 · 300 mcg/0.5 mL · injection, 0.5 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Filra · DIN 02556537
Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31
Health Canada: Marketed since 2025-09-16 · brand FILRA · ATC L03AA02 FILGRASTIM · form Solution · route Intravenous, Subcutaneous · ingredients FILGRASTIM 300 MCG/0.5ML · company Jamp pharma corporation · schedule Schedule d, Prescription
DIN 02556537: Filra
Raw flags: sec3=Y
Item: 201600067; group id 269; item number 0546; lccId None; manufacturer id JPC
Source form: Inj Sol-0.5mL Pref Syr (Preservative-Free); strength: 300mcg/0.5mL
Recorded listing: General benefit
Source prices (unrounded): $105.6798; ministry $105.6798
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556537
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556537
Shortage record checked October 6, 2026
Nypozi · DIN 02520990 · 300 mcg/0.5 mL · injection, 0.5 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Nypozi · DIN 02520990
Manufacturer: Tanvex BioPharma USA, Inc.; listing date 2024-01-31
Health Canada: Marketed since 2024-01-24 · brand NYPOZI · ATC L03AA02 FILGRASTIM · form Solution · route Intravenous, Subcutaneous · ingredients FILGRASTIM 300 MCG/0.5ML · company Tanvex biopharma usa, inc. · schedule Schedule d, Prescription
DIN 02520990: Nypozi
Raw flags: sec3=Y
Item: 201600065; group id 269; item number 0545; lccId None; manufacturer id TAV
Source form: Inj Sol-0.5mL Pref Syr (Preservative-Free); strength: 300mcg/0.5mL
Recorded listing: General benefit
Source prices (unrounded): $105.6798; ministry $105.6798
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02520990
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101023
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02520990
DIN 02485591: Nivestym
Raw flags: sec3=Y
Item: 201600057; group id 269; item number 0551; lccId None; manufacturer id PFI
Source form: Inj Sol-1mL Vial Pk; strength: 300mcg/mL
Recorded listing: General benefit
Source prices (unrounded): $105.6798; ministry $105.6798
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485591
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97583
Shortage status: active shortage (reported September 9, 2026, estimated to end October 26, 2026, last updated September 15, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485591
Shortage record checked October 6, 2026
Grastofil · DIN 02441489 · 300 mcg/0.5 mL · pre-filled syringe-0.5mL Pk
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Grastofil · DIN 02441489
Manufacturer: Apotex Inc.; listing date 2016-12-22
Health Canada: Marketed since 2016-03-17 · brand GRASTOFIL · ATC L03AA02 FILGRASTIM · form Solution · route Subcutaneous, Intravenous · ingredients FILGRASTIM 300 MCG/0.5ML · company Apotex inc · schedule Schedule d, Prescription
Grastofil: Formulary list price $105.68 per unit (the source does not state the unit; exact figure $105.6798). What the ministry pays, not the patient.
Ministry pays: $105.6798 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02441489: Grastofil
Raw flags: sec3=Y
Item: 201600051; group id 269; item number 0552; lccId None; manufacturer id APX
Source form: Pref Syr-0.5mL Pk; strength: 300mcg/0.5mL
Recorded listing: General benefit
Source prices (unrounded): $105.6798; ministry $105.6798
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02441489
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92587
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02441489
Shortage record checked October 6, 2026
Nivestym · DIN 02485583 · 480 mcg/0.8 mL · injection solution-0.8mL pre-filled syringe
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Nivestym · DIN 02485583
Manufacturer: Pfizer Canada Inc.; listing date 2020-07-31
Health Canada: Marketed since 2020-05-11 · brand NIVESTYM · ATC L03AA02 FILGRASTIM · form Solution · route Intravenous, Subcutaneous · ingredients FILGRASTIM 480 MCG/0.8ML · company Pfizer canada ulc · schedule Schedule d, Prescription
DIN 02485583: Nivestym
Raw flags: sec3=Y
Item: 201600058; group id 269; item number 0547; lccId None; manufacturer id PFI
Source form: Inj Sol-0.8mL Pref Syr; strength: 480mcg/0.8mL
Recorded listing: General benefit
Source prices (unrounded): $169.0872; ministry $169.0872
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485583
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97582
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485583
Shortage record checked October 6, 2026
Filra · DIN 02556545 · 480 mcg/0.8 mL · injection, 0.8 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Filra · DIN 02556545
Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31
Health Canada: Marketed since 2025-09-16 · brand FILRA · ATC L03AA02 FILGRASTIM · form Solution · route Intravenous, Subcutaneous · ingredients FILGRASTIM 480 MCG/0.8ML · company Jamp pharma corporation · schedule Schedule d, Prescription
DIN 02556545: Filra
Raw flags: sec3=Y
Item: 201600068; group id 269; item number 0549; lccId None; manufacturer id JPC
Source form: Inj Sol-0.8mL Pref Syr (Preservative-Free); strength: 480mcg/0.8mL
Recorded listing: General benefit
Source prices (unrounded): $169.0872; ministry $169.0872
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02556545
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104523
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02556545
Shortage record checked October 6, 2026
Nypozi · DIN 02521008 · 480 mcg/0.8 mL · injection, 0.8 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Nypozi · DIN 02521008
Manufacturer: Tanvex BioPharma USA, Inc.; listing date 2024-01-31
Health Canada: Marketed since 2024-01-24 · brand NYPOZI · ATC L03AA02 FILGRASTIM · form Solution · route Intravenous, Subcutaneous · ingredients FILGRASTIM 480 MCG/0.8ML · company Tanvex biopharma usa, inc. · schedule Schedule d, Prescription
DIN 02521008: Nypozi
Raw flags: sec3=Y
Item: 201600066; group id 269; item number 0548; lccId None; manufacturer id TAV
Source form: Inj Sol-0.8mL Pref Syr (Preservative-Free); strength: 480mcg/0.8mL
Recorded listing: General benefit
Source prices (unrounded): $169.0872; ministry $169.0872
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02521008
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101024
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02521008
Shortage record checked October 6, 2026
Nivestym · DIN 02485656 · 480 mcg/1.6 mL · injection solution-1.6mL vial
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Nivestym · DIN 02485656
Manufacturer: Pfizer Canada Inc.; listing date 2020-07-31
Health Canada: Marketed since 2020-06-10 · brand NIVESTYM · ATC L03AA02 FILGRASTIM · form Solution · route Subcutaneous, Intravenous · ingredients FILGRASTIM 480 MCG/1.6ML · company Pfizer canada ulc · schedule Prescription, Schedule d
DIN 02485656: Nivestym
Raw flags: sec3=Y
Item: 201600059; group id 269; item number 0550; lccId None; manufacturer id PFI
Source form: Inj Sol-1.6mL Vial Pk; strength: 480mcg/1.6mL
Recorded listing: General benefit
Source prices (unrounded): $169.0872; ministry $169.0872
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02485656
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97588
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485656
Shortage record checked October 6, 2026
Grastofil · DIN 02454548 · 480 mcg/0.8 mL · pre-filled syringe-0.8mL Pk
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Grastofil · DIN 02454548
Manufacturer: Apotex Inc.; listing date 2016-12-22
Health Canada: Marketed since 2016-11-28 · brand GRASTOFIL · ATC L03AA02 FILGRASTIM · form Solution · route Intravenous, Subcutaneous · ingredients FILGRASTIM 480 MCG/0.8ML · company Apotex inc · schedule Prescription, Schedule d
Grastofil: Formulary list price $169.09 per unit (the source does not state the unit; exact figure $169.0872). What the ministry pays, not the patient.
Ministry pays: $169.0872 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02454548: Grastofil
Raw flags: sec3=Y
Item: 201600052; group id 269; item number 0553; lccId None; manufacturer id APX
Source form: Pref Syr-0.8mL Pk; strength: 480mcg/0.8mL
Recorded listing: General benefit
Source prices (unrounded): $169.0872; ministry $169.0872
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02454548
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94117
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02454548
Shortage record checked October 6, 2026
Pegfilgrastim
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Lapelga · DIN 02529343 · 6 mg/0.6 mL · injection solution-0.6mL Pref Autoinj (Preservative-Free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Lapelga · DIN 02529343
Manufacturer: Apotex Inc.; listing date 2023-09-28
Health Canada: Marketed since 2022-11-28 · brand LAPELGA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Apotex inc · schedule Prescription, Schedule d
Lapelga: Formulary list price $1375.00 per unit (the source does not state the unit; exact figure $1375.0000). What the ministry pays, not the patient.
Ministry pays: $1375.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02529343: Lapelga
Raw flags: sec3=Y
Item: 201600064; group id 270; item number 0554; lccId None; manufacturer id APX
Source form: Inj Sol-0.6mL Pref Autoinj (Preservative-Free); strength: 6mg/0.6mL
Recorded listing: General benefit
Source prices (unrounded): $1375.0000; ministry $1375.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02529343
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101856
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529343
Shortage record checked October 6, 2026
Niopeg · DIN 02546973 · 6 mg/0.6 mL · injection, 0.6 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Niopeg · DIN 02546973
Manufacturer: Nora Pharma; listing date 2025-07-31
Health Canada: Marketed since 2025-02-12 · brand NIOPEG · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Nora pharma inc · schedule Prescription, Schedule d
DIN 02546973: Niopeg
Raw flags: sec3=Y
Item: 201600069; group id 270; item number 0556; lccId None; manufacturer id NRA
Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL
Recorded listing: General benefit
Source prices (unrounded): $492.0000; ministry $492.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02546973
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103564
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02546973
Shortage record checked October 6, 2026
Pexegra · DIN 02553945 · 6 mg/0.6 mL · injection, 0.6 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Pexegra · DIN 02553945
Manufacturer: Jamp Pharma Corporation; listing date 2025-07-31
Health Canada: Marketed since 2025-09-09 · brand PEXEGRA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 10 MG/ML · company Jamp pharma corporation · schedule Prescription, Schedule d
DIN 02553945: Pexegra
Raw flags: sec3=Y
Item: 201600070; group id 270; item number 0557; lccId None; manufacturer id JPC
Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL
Recorded listing: General benefit
Source prices (unrounded): $492.0000; ministry $492.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02553945
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104284
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553945
Shortage record checked October 6, 2026
Ziextenzo · DIN 02497395 · 6 mg/0.6 mL · injection, 0.6 mL pre-filled syringe (preservative-free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Ziextenzo · DIN 02497395
Manufacturer: Sandoz Canada Inc.; listing date 2020-08-28
Health Canada: Marketed since 2020-05-15 · brand ZIEXTENZO · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Sandoz canada incorporated · schedule Prescription, Schedule d
Ziextenzo: Formulary list price $492.00 per unit (the source does not state the unit; exact figure $492.0000). What the ministry pays, not the patient.
Ministry pays: $492.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02497395: Ziextenzo
Raw flags: sec3=Y
Item: 201600060; group id 270; item number 0555; lccId None; manufacturer id SDZ
Source form: Inj Sol-0.6mL Pref Syr (Preservative-Free); strength: 6mg/0.6mL
Recorded listing: General benefit
Source prices (unrounded): $492.0000; ministry $492.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02497395
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98722
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02497395
Shortage record checked October 6, 2026
Nyvepria · DIN 02506238 · 6 mg/0.6 mL · injection solution-0.6mL pre-filled syringe Pk (Preservative-Free)
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Nyvepria · DIN 02506238
Manufacturer: Pfizer Canada Inc.; listing date 2021-08-31
Health Canada: Marketed since 2021-01-18 · brand NYVEPRIA · ATC L03AA13 PEGFILGRASTIM · form Solution · route Subcutaneous · ingredients PEGFILGRASTIM 6 MG/0.6ML · company Pfizer canada ulc · schedule Schedule d, Prescription
DIN 02506238: Nyvepria
Raw flags: sec3=Y
Item: 201600061; group id 270; item number 0558; lccId None; manufacturer id PFI
Source form: Inj Sol-0.6mL Pref Syr Pk (Preservative-Free); strength: 6mg/0.6mL
Recorded listing: General benefit
Source prices (unrounded): $492.0000; ministry $492.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02506238
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99556
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506238
DIN 02484153: Fulphila
Raw flags: sec3=Y
Item: 201600055; group id 270; item number 0559; lccId None; manufacturer id BCL
Source form: Inj Sol-Pref Syr; strength: 10mg/mL
Recorded listing: General benefit
Source prices (unrounded): $492.0000; ministry $492.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02484153
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97449
Shortage status: resolved shortage (ended March 30, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02484153
DIN 02474565: Lapelga
Raw flags: sec3=Y
Item: 201600054; group id 270; item number 0560; lccId None; manufacturer id APX
Source form: Inj Sol-Pref Syr - 0.6mL Pk (Preservative Free); strength: 10mg/mL
Recorded listing: General benefit
Source prices (unrounded): $492.0000; ministry $492.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474565
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96479
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02474565
Shortage record checked October 6, 2026
Other drugs in the same formulary class (20:16 Hematopoietic Agents) and how they are covered
Matched class: 20:16 Hematopoietic Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
No displayed product is listed as a general benefit in this extract. Check its listing requirements below.
20:16 Hematopoietic Agents
1. Indications
Grastofil® (filgrastim injection) is indicated for:
• Cancer Patients Receiving Myelosuppressive Chemotherapy
Grastofil® is indicated to decrease the incidence of infection, as manifested by febrile
neutropenia, in patients with non-myeloid malignancies (see 7.1 Special Populations,
Patients with Acute Myeloid Leukemia) receiving myelosuppressive anti-neoplastic drugs.
Grastofil® is indicated in adult and pediatric patients with cancer receiving myelosuppressive
chemotherapy. A complete blood count (CBC) and platelet count should be obtained prior to
chemotherapy, and twice per week (see 7 Warnings and Precautions, Monitoring and
Laboratory Tests) during Grastofil® therapy to avoid leukocytosis and to monitor the
neutrophil count. In phase 3 clinical studies, Grastofil® therapy was discontinued when the
ANC was > 10 x 109/L after expected chemotherapy-induced nadir.
• Patients with Acute Myeloid Leukemia
Grastofil® is indicated for the reduction in the duration of neutropenia, fever, antibiotic use
and hospitalization, following induction and consolidation treatment for acute myeloid
leukemia.
• Cancer Patien…
https://pdf.hres.ca/dpd_pm/00083708.PDF
PM date: 2026-02-24
Source product: GRASTOFIL; DIN 02441489; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1. Indications
LAPELGA® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by
febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-
neoplastic drugs.
1.1 Pediatrics (< 18 years of age)
No data are available to Health Canada; therefore, Health Canada has not authorized an
indication for pediatric use.
1.2 Geriatrics (> 65 year of age)
No data are available to Health Canada; therefore Health Canada has not authorized on
indication for geriatric use.
https://pdf.hres.ca/dpd_pm/00083321.PDF
PM date: 2026-01-29
Source product: LAPELGA; DIN 02474565; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Nivestym · DIN 02485591
Shortage status: active shortage (reported 2026-09-09, estimated to end 2026-10-26, last updated 2026-09-15); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485591